Paroxetine-d4 (hydrochloride)
CAT:
804-HY-B0492S1
Size:
1 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

Paroxetine-d4 (hydrochloride)
- CAS Number: 2714485-95-5
- UNSPSC Description: Paroxetine-d4 (hydrochloride) is deuterium labeled Paroxetine (hydrochloride). Paroxetine hydrochloride is a potent selective serotonin-reuptake inhibitor, commonly prescribed as an and has GRK2 inhibitory ability with IC50 of 14 μM. Paroxetine hydrochloride can be used for the research of depressive disorder[1][2][3].
- Target Antigen: Autophagy; Isotope-Labeled Compounds; Serotonin Transporter
- Type: Isotope-Labeled Compounds
- Related Pathways: Autophagy;Neuronal Signaling;Others
- Applications: Cancer-programmed cell death
- Field of Research: Neurological Disease; Cancer
- Purity: 99.16
- Solubility: 10 mM in DMSO
- Smiles: FC(C([2H])=C1[2H])=C([2H])C([2H])=C1[C@H](CCNC2)[C@@H]2COC3=CC=C(OCO4)C4=C3.Cl
- Molecular Weight: 369.85
- References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Lassen TR, et al. Effect of paroxetine on left ventricular remodeling in an in vivo rat model of myocardial infarction. Basic Res Cardiol. 2017 May;112(3):26.|[3]Liu RP, et al. Paroxetine ameliorates lipopolysaccharide-induced microglia activation via differential regulation of MAPK signaling. J Neuroinflammation. 2014 Mar 12;11:47.|[4]Waldschmidt HV, et al. Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine. J Med Chem. 2017 Apr 13;60(7):3052-3069.|[5]Wang Q, et al. Paroxetine alleviates T lymphocyte activation and infiltration to joints of collagen-induced arthritis. Sci Rep. 2017 Mar 28;7:45364.|[6]Zarei M, et al. Paroxetine attenuates the development and existing pain in a rat model of neurophatic pain. Iran Biomed J. 2014;18(2):94-100.
- Shipping Conditions: Room Temperature
- Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
- Clinical Information: No Development Reported